How Ipamorelin Affects IGF-1

Ipamorelin raises IGF-1 through selective pulsatile GH stimulation:

1. Selective GHS-R1a agonism: Ipamorelin activates the ghrelin receptor to trigger GH release from somatotroph cells in the anterior pituitary. Its selectivity is unique among GHRPs: it does not stimulate ACTH, cortisol, or prolactin release even at doses 200-fold above the effective GH dose (Raun et al., 1998).
2. Pulsatile release pattern: Each ipamorelin injection produces a discrete GH pulse that peaks at approximately 40 minutes and returns to baseline within 2-3 hours (Gobburu et al., 1999). This pulsatile pattern mimics normal physiological GH secretion.
3. Hepatic IGF-1 response: The GH pulses stimulate hepatic IGF-1 synthesis. Because the GH signal is pulsatile (not sustained), the liver has recovery periods between stimulations, producing a more physiological IGF-1 elevation compared to MK-677 or exogenous GH at high doses.
4. Synergy with GHRH: Ipamorelin is commonly paired with CJC-1295 (modified GRF 1-29) to amplify the GH pulse. GHRH primes the somatotroph while ipamorelin triggers release, producing a larger pulse than either compound alone.

Standard dose (200-300 mcg, 1-3 times daily):

• IGF-1 typically increases 15-40% above baseline
• The magnitude depends on injection frequency, timing, and whether combined with a GHRH analog
• Most users reach the upper-normal range for their age without exceeding it

Combined with CJC-1295 (no DAC):

• IGF-1 response is amplified, potentially reaching 30-60% above baseline
• Still lower than MK-677 at 25 mg/day due to the pulsatile pattern allowing inter-dose recovery

Compared to MK-677:

• Lower absolute IGF-1 elevation at equivalent "effective" doses
• More physiological IGF-1 pattern (pulsatile rather than sustained)
• Significantly less insulin resistance per unit of IGF-1 elevation

Timeline: IGF-1 begins rising within 1-2 weeks of consistent dosing and stabilises by 3-4 weeks.

Baseline: Obtain IGF-1 before starting. Age-matched reference ranges apply.

During use:

• IGF-1 at 4 weeks (to confirm response), then every 3-6 months
• Fasting glucose at baseline and quarterly (minimal impact expected, but confirms metabolic safety)
• No thyroid or hormonal monitoring required (ipamorelin does not affect TSH, LH, FSH, or prolactin)

Key advantage for monitoring: Ipamorelin requires fewer monitoring markers than MK-677 because it lacks the metabolic and hormonal side effects. IGF-1 is the primary marker of efficacy and safety.

Optimising the IGF-1 response:

• Inject on an empty stomach or 2+ hours after eating (food, especially fats, blunts the GH response)
• Bedtime dosing aligns with natural nocturnal GH release for a synergistic effect
• If using 2-3 daily doses, spread them 4-6 hours apart to maintain pulsatile pattern
• Pair with CJC-1295 (no DAC) at 100 mcg per injection for amplified GH pulses

If IGF-1 response is poor:

• Ensure proper reconstitution, storage, and injection technique
• Verify product authenticity
• Add CJC-1295 (no DAC) if not already using it
• Check that you are injecting in a fasted state